Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.